Health status and costs of exacerbations of chronic bronchitis and COPD: how to improve antibiotic treatment

References

• Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 23, 932–946 (2004).
   PubMed Web of Science ®Google Scholar
• Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. Am. J. Respir. Crit. Care Med. 156, 814–818 (1997).
   PubMed Web of Science ®Google Scholar
• Sobradillo V, Miravitlles M, Gabriel R et al. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 118, 981–989 (2000).
   PubMed Web of Science ®Google Scholar
• Jiménez-Ruiz CA, Masa F, Miravitlles M et al. Smoking characteristics: attitudes and dependence. Differences between healthy smokers and smokers with COPD. Chest 119, 1365–1370 (2001).
   PubMed Web of Science ®Google Scholar
• Cerveri I, Accordini S, Verlato G et al. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur. Respir. J. 18, 85–92 (2001).
   PubMed Web of Science ®Google Scholar
• Feenstra TL, van Genugten MLL, Hoogenveen RT, Wouters EF, Rutten van Mölken MPMH. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164, 590–596 (2001).
   PubMed Web of Science ®Google Scholar
• Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157, 1418–1422 (1998).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ferrer M, Pont A et al. Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study. Thorax 59, 387–395 (2004).
   PubMed Web of Science ®Google Scholar
• Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N. Engl. J. Med. 317, 1309–1314 (1987).
   PubMed Web of Science ®Google Scholar
• Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. QJM 88, 61–68 (1995).
   PubMed Web of Science ®Google Scholar
• Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in out-patients with acute exacerbations of COPD. Chest 117, 1345–1352 (2000).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Murio C, Guerrero T on Behalf of the DAFNE Study Group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur. Respir. J. 17, 928–933 (2001).
   PubMed Web of Science ®Google Scholar
• Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am. Rev. Respir. Dis. 119, 895–902 (1979).
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and excercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 350, 1005–1012 (2004).
   PubMed Web of Science ®Google Scholar
• Engström CP, Persson LO, Larsson S, Sullivan M. Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur. Respir. J. 18, 69–76 (2001).
   PubMed Web of Science ®Google Scholar
• Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 56, 880–887 (2001).
   PubMed Web of Science ®Google Scholar
• Doll H, Miravitlles M. Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 23, 345–363 (2005).
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. Am. Rev. Respir. Dis. 145, 1321–1327 (1992).
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Berman LB, Towsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 42, 773–778 (1987).
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J. Clin. Epidemiol. 47, 81–87 (1994).
   PubMed Web of Science ®Google Scholar
• Doll H, Grey-Amante P, Duprat-Lomon I et al. Quality of life in acute exacerbations of chronic bronchitis: results from a German population study. Respir. Med. 96, 39–51 (2002).
   PubMed Web of Science ®Google Scholar
• Doll H, Duprat-Lomon I, Ammerman E, Sagnier PP. Validity of the St George’s respiratory questionnaire at acute exacerbation of chronic bronchitis: comparison with the Nottingham health profile. Qual. Life Res. 12, 117–132 (2003).
   PubMed Web of Science ®Google Scholar
• Grossman R, Mukherjee J, Vaughan D et al. A 1-year community-based health economic study of ciprofloxacin vs. usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 113, 131–141 (1998).
   PubMed Web of Science ®Google Scholar
• Miravitlles M. Designing future clinical trials for acute exacerbations of chronic bronchitis. In: Mechanisms and Management of COPD Exacerbations. Allegra L, Blasi F (Eds). Springer-Verlag, Milan, Italy, 88–99 (2000).
   Google Scholar
• Aaron SD, Vandemheen KL, Clinch JJ et al. Measurment of short-term changes in dyspnoea and disease-specific quality of life following an acute COPD exacerbation. Chest 121, 688–696 (2002).
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Hebert N et al. Out-patient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N. Engl. J. Med. 348, 2618–2625 (2003).
   PubMed Web of Science ®Google Scholar
• Spencer S, Jones PW for the GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 58, 589–593 (2003).
   PubMed Web of Science ®Google Scholar
• Andersson I, Johansson K, Larsson S, Pehrsson K. Long-term oxygen therapy and quality of life in elderly patients hospitalised due to severe exacerbation of COPD. A 1 year follow-up study. Respir. Med. 96, 944–949 (2002).
   PubMedGoogle Scholar
• Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 161, 1608–1613 (2000).
   PubMed Web of Science ®Google Scholar
• Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur. Respir. J. 19, 398–404 (2002).
   PubMed Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following six months treatment with once daily tiotropium compared to twice daily salmeterol in patients with COPD. Thorax 58, 399–404 (2003).
   PubMed Web of Science ®Google Scholar
• Spencer S, Calverley PMA, Burge PS, Jones PW on behalf of the ISOLDE Study Group. Health status deterioration in patients with chronic obstructive pulmonay disease. Am. J. Respir. Crit. Care Med. 163, 122–128 (2001).
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M et al. Longitudinal changes in health status using the Chronic Respiratory Disease Questionnaire and pulmonary function in patients with stable chronic obstructive pulmonary disease. Qual. Life Res. 13, 1109–1116 (2004).
   PubMed Web of Science ®Google Scholar
• Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 52, 67–71 (1997).
   PubMed Web of Science ®Google Scholar
• Tu SP, McDonell MB, Spertus JA et al. A new self-administered questionnaire to monitor health-related quality of life in patients with COPD: Ambulatory Care Quality Improvement Project (ACQUIP) Investigators. Chest 112, 614–622 (1997).
   PubMedGoogle Scholar
• Fan VS, Curtis JR, Tu SP, McDonell MB, Fihn SD for the Ambulatory Care Quality Improvement Project Investigators. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest 122, 429–436 (2002).
   PubMed Web of Science ®Google Scholar
• Domingo-Salvany A, Lamarca R, Ferrer M et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166, 680–685 (2002).
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M et al. Health status measured with the CRQ does not predict mortality in COPD. Eur. Respir. J. 20, 1147–1151 (2002).
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320, 1297–1303 (2000).
   PubMed Web of Science ®Google Scholar
• Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 351, 773–780 (1998).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL on Behalf of the EOLO Group. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir. Med. 93, 173–179 (1999).
   PubMed Web of Science ®Google Scholar
• Fuso L, Incalzi RA, Pistelli R et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am. J. Med. 98, 272–277 (1995).
   PubMed Web of Science ®Google Scholar
• Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbations of chronic obstructive pulmonary disease. JAMA 274, 1852–1857 (1995).
   PubMed Web of Science ®Google Scholar
• Vilkman S, Keistinen T, Tuuponen T, Kivelä SL. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration 64, 281–284 (1997).
   PubMed Web of Science ®Google Scholar
• Vestbo J, Prescott E, Lange P, Schnohr P, Jensen G. Vital prognosis after hospitalization for COPD: a study of a random population sample. Respir. Med. 92, 772–776 (1998).
   PubMed Web of Science ®Google Scholar
• Connors Jr AF, Dawson NV, Thomas C et al. Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 154, 959–967 (1996).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL on Behalf of the EOLO Group. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 67, 495–501 (2000).
   PubMed Web of Science ®Google Scholar
• Antonelli Incalzi R, Fuso L, De Rosa M et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 10, 2794–2800 (1997).
   PubMed Web of Science ®Google Scholar
• Loukides S, Polyzogopoulos D. The effect of diabetes mellitus on the outcome of patients with chronic obstructive pulmonary disease exacerbated due to respiratory infections. Respiration 63, 170–173 (1996).
   PubMed Web of Science ®Google Scholar
• Ferrer M, Alonso J, Morera J et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann. Intern. Med. 127, 1072–1079 (1997).
   PubMed Web of Science ®Google Scholar
• Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur. Respir. J. 8, 1333–1338 (1995).
   PubMed Web of Science ®Google Scholar
• Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 45, 579–585 (1990).
   PubMed Web of Science ®Google Scholar
• Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 159, 1267–1271 (1999).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Espinosa C, Fernández-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 116, 40–46 (1999).
   PubMed Web of Science ®Google Scholar
• DeAbate CA, Henry D, Bensch G et al. Sparfloxacin vs. ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. A multicenter, double-blind, randomized, comparative study. Chest 114, 120–130 (1998).
   PubMedGoogle Scholar
• Chodosh S, DeAbate CA, Haverstock D, Aneiro L, Church D, The Bronchitis Study Group. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir. Med. 94, 18–27 (2000).
   PubMed Web of Science ®Google Scholar
• Sachs APE, Köter GH, Groenier KH, van der Waaij D, Schiphuis J, Meyboom-de Jong B. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 50, 758–763 (1995).
   PubMed Web of Science ®Google Scholar
• Macfarlane J, Holmes W, Gard P et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 56, 109–114 (2001).
   PubMed Web of Science ®Google Scholar
• Murata GH, Gorby MS, Kapsner CO, Chick TW, Halperin AK. A multivariate model for predicting hospital admissions for patients with decompensated chronic obstructive pulmonary disease. Arch. Intern. Med. 152, 82–86 (1992).
   PubMedGoogle Scholar
• Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106, 196–204 (1987).
   PubMed Web of Science ®Google Scholar
• Hilleman DE, Dewan N, Malesker M et al. Pharmacoeconomic evaluation of COPD. Chest 118, 1278–1285 (2000).
   PubMed Web of Science ®Google Scholar
• Jacobson L, Hertzman P, Löfdahl CG et al. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir. Med. 94, 247–255 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir. Med. 94, 204–213 (2000).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Murio C, Guerrero T, Gisbert R on behalf of the DAFNE study group. Costs of chronic bronchitis and COPD. A one year follow-up study. Chest 123, 784–791 (2003).
   PubMed Web of Science ®Google Scholar
• Masa JF, Sobradillo V, Villasante C et al. Costs of chronic obstructive pulmonary disease in Spain: estimation from a population-based study. Arch. Bronconeumol. 40, 72–79 (2004).
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Rutten-van Mölken MPMH. Resource use and risk factors in high-cost exacerbations of COPD. Respir. Med. 98, 883–891 (2004).
   PubMed Web of Science ®Google Scholar
• Andersson F, Borg S, Jansson S-A et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir. Med. 96, 700–708 (2002).
   PubMed Web of Science ®Google Scholar
• Izquierdo-Alonso JL, de Miguel-Díez J. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. COPD 1, 215–223 (2004).
   PubMedGoogle Scholar
• Miravitlles M, Murio C, Guerrero T, Gisbert R on behalf of the DAFNE study group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121, 1449–1455 (2002).
   PubMed Web of Science ®Google Scholar
• García-Aymerich J, Barreiro E, Farrero E, Marrades RM, Morera J, Antó JM. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur. Respir. J. 16, 1037–1042 (2000).
   PubMed Web of Science ®Google Scholar
• Drummond MF, Becker DL, Hux M et al. An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 124, 526–535 (2003).
   PubMed Web of Science ®Google Scholar
• Dewan NA, Rafique S, Kanwar B et al. Acute exacerbations of COPD. Factors associated with poor treatment outcome. Chest 117, 662–671 (2000).
   PubMed Web of Science ®Google Scholar
• Davey PG. Cost management in community-acquired lower respiratory tract infection. Am. J. Med. 99(Suppl. 6B), S20–S23 (1995).
   Google Scholar
• Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 359, 1648–1654 (2002).
   PubMed Web of Science ®Google Scholar
• Bjerrum L, Boada A, Cots JM et al. Respiratory tract infections in general practice: considerable differences in prescribing habits between general practitioners in Denmark and Spain. Eur. J. Clin. Pharmacol. 60, 23–28 (2004).
   PubMed Web of Science ®Google Scholar
• Allegra L, Grassi C, Grossi E et al. Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico. Ital. J. Chest Dis. 45, 138–148 (1991).
   Google Scholar
• Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-ananlysis. JAMA 273, 957–960 (1995).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Torres A. No more equivalence trials for antibiotics in exacerbations of COPD, please. Chest 125, 811–813 (2004).
   PubMedGoogle Scholar
• Miravitlles M, Zalacain R, Murio C et al. Speed of recovery from acute exacerbations of COPD after treatment with antimicrobials: results of a two-year study. Clin. Drug Invest. 23, 439–450 (2003).
   PubMed Web of Science ®Google Scholar
• Llor C, Naberan K, Cots JM, Molina J, Miravitlles M. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care centers. Int. J. Clin. Pract. 58, 937–944 (2004).
   PubMed Web of Science ®Google Scholar
• Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can. Respir. J. 10(Suppl. B), 3B–32B (2003).
   PubMedGoogle Scholar
• ALAT Work Group. Update to the Latin American Thoracic Society (ALAT) recommendations on infectious exacerbation of COPD. Arch. Bronconeumol. 40, 315–325 (2004).
   PubMedGoogle Scholar
• Anzueto A, Rizzo JA, Grossman RF. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. Clin. Infect. Dis. 28, 1344–1345 (1999).
   PubMed Web of Science ®Google Scholar
• Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin. Ther. 24, 639–652 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson R, Allegra L, Huchon G et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 125, 953–964 (2004).
   PubMed Web of Science ®Google Scholar
• Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and out-patient management of acute exacerbations of COPD. Chest 117, 1638–1645 (2000).
   PubMed Web of Science ®Google Scholar
• Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57, 759–764 (2002).
   PubMed Web of Science ®Google Scholar
• Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur. Respir. J. 20(Suppl. 36), S9–S19 (2002).
   Web of Science ®Google Scholar
• Soler JJ, Sánchez L, Román P, Martínez MA, Perpiñá M. Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. Respir. Med. 98, 318–329 (2004).
   PubMed Web of Science ®Google Scholar